EuroQol 5D-3L Results from Clinical Trial for Long COVID Treatment after supplementation with Dietary Supplement based on Sea Urchin Eggs Extract NCT05531019 for EuroQol5Dimensions (EQ-5D) and demographic data analysis

Patients with Long COVID experience a significant decrease in their quality of life and the lack of effective treatment represents an unmet need in medical care and patient health. One proposed strategy for treating Long COVID is to increase the body's ability to restore immune balance by controlling inflammation with anti-inflammatory substances. For this reason, the aim of this double-blind study was to evaluate the supplementation of patients with EchA Marine®, a dietary supplement based on sea urchin eggs rich in Echinochrome A. This compound has demonstrated anti-inflammatory and antioxidant properties by activating the metabolism of glutathione and improving mitochondrial mass and performance. The EuroQol 5-Dimension (EQ-5D) is a standardized questionnaire assessing five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used as an instrument to measure health-related quality of life in clinical and economic studies. In this multicenter, double-blind, intervention study, we have demonstrated that the dietary supplement EchA Marine® can significantly enhance the quality of life of these patients, particularly in pain and discomfort; notably improving their quality of life and daily activity’s ability. EchA Marine® is an effective treatment option for Long COVID patients and with further research its efficacy could be further strengthened. Clinical trial registration number: NCT05531019. First posted September 7th, 2022.

患有长期新冠的病患经历了生活质量显著下降，而缺乏有效的治疗方案则构成了医疗护理和患者健康中的一个未满足需求。针对长期新冠的治疗策略之一是，通过控制抗炎物质来调节炎症，从而增强身体恢复免疫平衡的能力。鉴于此，本研究旨在评估向患者补充 EchA Marine®（一种基于富含 Echinochrome A 的海胆卵的膳食补充剂）的效果。该化合物通过激活谷胱甘肽的代谢、改善线粒体质量和性能，已显示出抗炎和抗氧化特性。EuroQol 5-Dimension（EQ-5D）是一种标准化的问卷，用于评估健康的五个维度：行动能力、自我护理、日常活动、疼痛/不适以及焦虑/抑郁，在临床和经济研究中被用作衡量与健康相关的生活质量的工具。在本多中心、双盲干预研究中，我们证明了膳食补充剂 EchA Marine® 可以显著提高这些患者的生存质量，特别是在疼痛和不适方面；显著提升了他们的生活质量及日常活动能力。EchA Marine® 是长期新冠患者的一种有效治疗选择，随着进一步研究的深入，其疗效有望得到进一步加强。临床试验注册号：NCT05531019。首次发布日期：2022年9月7日。